The adipocyte cGMP-inhibited cyclic nucleotide phosphodiesterase (PDE3B) as a target for lipolytic and thermogenic agents for the treatment of obesity

Author： Snyder P.B.  

Publisher： Informa Healthcare

ISSN： 1472-8222

Source： Expert Opinion on Therapeutic Targets, Vol.3, Iss.4, 1999-12, pp. : 587-599

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Inhibitors of cyclic nucleotide phosphodiesterase PDE3 as adjunct therapy for dilated cardiomyopathy

By Movsesian Matthew A   Alharethi Rami  

Expert Opinion on Investigational Drugs, Vol. 11, Iss. 11, 2002-11 ,pp. : 1529-1536

Informa Healthcare

Access to resources Recommend Favorite

Cyclic Nucleotide Phosphodiesterase in Human Bronchial Epithelial Cells: Characterization of Isoenzymes and Functional Effects of PDE Inhibitors

By dent G.   White S.R.   Tenor H.   Bodtke K.   Schudt C.   Leff A.R.   Magnussen H.   Rabe K.F.  

Pulmonary Pharmacology & Therapeutics, Vol. 11, Iss. 1, 1998-02 ,pp. : 47-56

Academic Press

Access to resources Recommend Favorite

Cyclic Nucleotide Phosphodiesterases (PDE) and Peptide Motifs

By  

Current Pharmaceutical Design, Vol. 16, Iss. 9, 2010-03 ,pp. : 1114-1125

Bentham Science Publishers

Access to resources Recommend Favorite

Cardiovascular activity of WIN 65579, a novel inhibitor of cyclic GMP phosphodiesterase 5

By Silver P.J.   Pagani E.D.   Dundore R.L.   de Garavilla L.   Bode D.C.   Bacon E.R.  

European Journal of Pharmacology, Vol. 349, Iss. 2, 1998-05 ,pp. : 263-268

Elsevier

Access to resources Recommend Favorite

Does Phosphodiesterase 11A (PDE11A) Hold Promise as a Future Therapeutic Target?

By  

Current Pharmaceutical Design, Vol. 21, Iss. 3, 2015-01 ,pp. : 389-416

Bentham Science Publishers

Access to resources Recommend Favorite